Allergy season started earlier than usual in 2025, and 2026 may follow suit, says an allergist. Here are five tips she recommends for managing allergy symptoms.
Among adults with chronic rhinosinusitis with nasal polyps, those receiving verekitug vs. placebo at baseline and week 12 had significantly decreased nasal polyp size at week 24, according to a poster ...
An asthma medication improves asthma control, respiratory quality of life, and upper airway symptoms in patients with chronic ...
Unlike traditional methods, phototherapy is chemical-free and non-invasive. Patients are not required to swallow tablets or endure injections, making it particularly useful for children, ...
Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery ...
If you’ve had a runny nose for years, it may not be “just a cold.” An ENT expert explains why it happens, how to identify the cause, and when to seek medical help.
The chronic rhinosinusitis with nasal polyps market growth is being driven by rising disease prevalence, greater awareness, and improved diagnostic rates.
The chronic rhinosinusitis with nasal polyps market growth is being driven by rising disease prevalence, greater awareness, and improved diagnostic rates. Advancements in biologic therapies are ...
A blocked nose that never seems to clear up could be more than just a cold Expert explains the hidden causes of chronic nasal congestion and when it’s time to seek medical help Read ahead to find out ...
The FDA has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis.
Phase 3 LIBERTY-AIMS results showed dupilumab reduced nasal polyp size and sinus symptoms in adults and children with allergic fungal rhinosinusitis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results